We got the similar result when a mutant form B7H3-4NQ was stably added back in mouse mammary basal-like carcinoma 4T1-B7H3KO cells, as indicated by the mobility of B7H3 reduced from ~55 to ~40 kDa (Fig. J. Immunol. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. To validate the combined effect of targeting FUT8 and checkpoint inhibitors in vivo, tumor xenografts were established by 1 × 105 B7H3-WT re-expressed or B7H3-4NQ re-expressed 4T1-B7H3KO cells in BALB/c mice. Nat. News Corp is a global, diversified media and information services company focused on creating and distributing . Triple-negative breast cancer is a subtype of breast cancer. 5, eaax8930 (2019). Breast cancer is "triple-negative" when the cancer cells don't have any of these . bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. The treatment is approved for people with triple-negative breast cancer that is locally . D.P.M. e Representative images of IHC staining of B7H3 expression in B7H3-WT re-expressed 4T1-B7H3KO xenograft tumor sections after treatment (left, n = 5 mice per group). In den meisten Fällen handelte es sich um einen Rückfall mit Tochtergeschwülsten (Metastasen) in anderen Organen. Natl Acad. Article  Mol. All knockout clones were identified by immunoblot. Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly. All terms have an enrichment P value <3.4e-03. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis. 12, 145 (2021). To further supported the involvement of FUT8 in B7H3 regulation, we generated mutant forms of FUT8 (R365A and 8MU inactive mutants). Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Natl Acad. Cha, J. H. et al. 5a, Supplementary Table 3). The Kaplan–Meier survival analysis further revealed that the TNBC patients with a high expression of B7H3 had a shortened OS compared to that with low expression (Fig. Helge Danker Dr. rer. Indeed, the tumors induced by the re-expression glycosylated B7H3 cells not only had decreased total CD4+ T, CD8+ T, and NK populations (Fig. (E) Ranked plot of the gene expression values for all genes involved in activated terms derived from IPA. Slider with three articles shown per slide. The prepared tumor cells and activated T cells were seeded into U-shaped 96-well microtiter plates at a ratio of 1:10–1:30 in triplicates. f Tumor growth of indicated mouse 4T1- B7H3KO cells in BALB/c mice. Surgical Oncol. FUT8 knockout attenuated core glycosylated B7H3 expression and strengthened immune response activation. For reconstituted with B7H3-WT and B7H3-8NQ in B7H3-deficient MDA-MB-231 and HCC1806 cells, packaging plasmids were co-transfected with pCDH-B7H3-WT-Flag (h) and pCDH-B7H3-8NQ-Flag (h) into HEK293T cells55. 4b), but had no effect on B7H3 mRNA level (fold change was not more than two times) (Supplementary Fig. The cells were seeded into six-well plates the day before transfection. Womöglich kann der zusätzliche Einsatz einer PD1-Blocker-Immuntherapie in der neoadjuvanten und adjuvanten Behandlung Patientinnen mit triple-negativem Brustkrebs im Frühstadium Überlebensvorteile verschaffen, so die Schlussfolgerung der Studienautoren. Downgrade as Debt-Ceiling Talks Drag - WSJ. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Definitive evidence that a single N-glycan among three glycans on inducible costimulator is required for proper protein trafficking and ligand binding. Clinical information of the samples was summarized in Supplementary Table 6. The p value in (e–g) was determined by a two-tailed unpaired Student’s t test. As a chemoattractant, 600 μl culture media containing 10% FBS was placed in the lower chamber60. We hence provide an insight into the transcriptional and epigenetic regulation of ET and identify putative underlying molecular pathways that should be investigated further for the potential for therapeutic targeting. (D) Boxplots of the β value distributions of all genes promoters (light blue), upregulated promoters (green), and downregulated promoters (red). The correlation was assessed using Pearson’s correlation test (two-sided). ISSN 2041-1723 (online). In summary, our studies confirm that FUT8-mediated aberrant core fucosylation of B7H3 is a key immunosuppressive factor in TNBC tumors. CAS  Clinical and hematologic parameters of patients enrolled in the study. B7H3 is a highly glycosylated . The top triple-A credit ratings of the U.S. were placed on "rating watch negative" by credit firm Fitch Ratings Wednesday evening, due to "brinkmanship" in Washington, over raising the . *Indicates the Student t test P value when comparing each set vs the set with hypermethylated promoters (light blue). No-template and no-reverse-transcriptase controls were used to ensure specific amplification of target transcripts. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. Database search parameters were set as follows: a maximum of four missed cleavage sites permitted from Chymotrypsin digestion (FYWML), 20 ppm precursor mass tolerance, 20 ppm fragment mass tolerance, carbamidomethylation (C, +57.022 Da) as a fixed modification, and oxidization (M, +15.995 Da) and deamidation 18O (N, +2.988 Da) as dynamic modifications. Chapoval, A. I. et al. CAS  Contribution: S.A. designed the study, collected and processed samples, conducted experiments, analyzed data, and wrote the manuscript; W.V. The overall survival of patients with both FUT8highB7H3high expression was not significantly different from that of patients with FUT8highB7H3low expression. Glycobiology 27, 601–618 (2017). doi: https://doi.org/10.1182/bloodadvances.2020003172. The p value in (a–c) was determined by a two-tailed unpaired Student’s t test. 5e). Google Scholar. Notably, the combination of core fucosylation inhibitor 2F-Fuc and anti-PDL1 results in enhanced therapeutic efficacy in B7H3-positive TNBC tumors. We thank Dr. Peng Sun and Dr. Ji-Bin Li (Sun Yat-sen University Cancer Center) for providing helpful and intensive discussions. 39, 1754–1764 (2009). We also observed a significant correlation between the expression levels of FUT8 and B7H3. Wang, H. et al. Cancer 15, 540–555 (2015). Inhibition of B7H3 core fucosylation by 2F-Fuc reduces cell-surface expression of B7H3 and enhances T-cell activation, leading to more efficient tumor eradication. The authors declare no competing interests. Suh, W. K. et al. To obtain Red closed circle, glycosylated B7H3. The full-text version of this article contains a data supplement. To date, the mechanisms for the induction and maintenance of high glycosylated B7H3 expression in cancer cells are not fully understood. There may exist eight NXT motif sites in human B7H3 (Asn positions 91, 104, 189, 215, 309, 322, 407, and 433) and four NXT motif sites in mouse B7H3 (Asn positions 91, 104, 189, and 215) with the prediction (Fig. 2e, bottom). For activated caspase-3 assay, FITC active caspase-3 apoptosis kit (Cat#550480) was purchased from BD Biosciences. Antibodies used in immunoblot and immunoprecipitation were listed Supplementary Table 4. a, b Kaplan–Meier analyses (two-sided) of RFS (a) and DMFS (b) based on B7H3 mRNA levels, using the KM-plotter breast cancer database (http://kmplot.com/analysis/). Google Scholar. The cycle threshold values for the 20 candidate genes (CEBPβ, ELK1, FAXDC2, FOSL2, GP1BB, GTPBP1, ITGA2B, ITGA7, ITGB3, JUN, JUND, KLF1, MAPKAPK2, MARCKS, NFκB2, PFKFB3, RELA, SPI1, TAL1, and TGFB1) are listed in supplemental Table 3. Cancer Res. The p value in a–c, g was assessed using the log-rank test. Biochem. Das TNBC stellt etwa 15-20% der Mammakarzinome. B7H3 protein was then measured by the indicated antibody. Article  Nat. The intact 18O-labeled peptides were analyzed by nano LC-MS/MS using a Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific, USA). provided experimental materials. B7H3 is also reported to inhibit polyclonal or allogeneic T-cell activation, proliferation, and effector cytokine production in humans24,25. 2g, upper). Er tritt vor allem bei jungen Frauen auf. CAR-T cells targeting B7H3 (B7H3.CAR-Ts) also showed effectively control tumor cells in vitro and in mice without obvious toxicity53,54. Ergänzend zu Studiendaten und Leitlinienempfehlungen stellen wir den Fall eines Patienten von Dr. Albrecht Wiethe, niedergelassener Urologe in Landsberg/Lech, vor, der ein neu diagnostiziertes mHSPC mit hohem Risiko und hoher Metastasenlast sowie einen PSA-Wert über 20.000 ng/ml hat. Moreover, the glycosylation of B7H3 had no effect on tumor formation in nude mice, as confirmed by the xenograft tumor volume and tumor weight (Supplementary Fig. 4g), but also had fewer activated cytotoxic CD8 T cells in their tumor-infiltrating lymphocytes (TILs) populations (IFNγ+CD8+ T and granzyme B+CD8+ T) than those tumors with re-expression of non-glycosylated B7H3 (Fig. 1e). Juni 2023 findet der EHA-Congress 2023 in Wien als hybride Veranstaltung statt. 3,11 Both triple-negative 12 and basal-like 13 breast . Statistical analyses were conducted using GraphPad Prism 8.0.1 (GraphPad, La Jolla, CA, USA) and SPSS 20 software. B7-H3 expression in ductal and lobular breast cancer and its association with IL-10. Melissa A. For 4T1 tumor xenografts, the tumor mass was isolated from mice and immersed with formalin and embedded into paraffin block. A fundamental aspect of gene regulation is by TFs and repressors. Hoti, N. et al. The correlation of B7H3 with FUT8 expression status in TNBC patient tumors (right). 4g). Natl Acad. Also B7H3 mRNA expression level was not prognostic in unselected patients (all patients), but a high expression level was significantly associated with the poor overall survival (OS) in patients with basal-like or ER−/HER2− tumors (Fig. and Y.F. The relevant solvent and control rat IgG2b antibody (BioXcell) were administered to control animals. The automatic gain control (AGC) was set as 3e6, and the maximum injection time (MIT) was 80 ms. Jun Tang, Xiao-Feng Zhu or Rong Deng. & Shan, B. E. B7-H3-mediated tumor immunology: friend or foe? Search for other works by this author on: MPNs as inflammatory diseases: the evidence, consequences, and perspectives, Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors, Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome, Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms, Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management, Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms, Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms, Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures, limma powers differential expression analyses for RNA-sequencing and microarray studies, Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy, Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program, The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms, Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory, Philadelphia-negative myeloproliferative neoplasms: laboratory workup in the era of next-generation sequencing, Gene body methylation can alter gene expression and is a therapeutic target in cancer, Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer [published correction appears in, Mediator kinase inhibition further activates super-enhancer-associated genes in AML, Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms, Congenital amegakaryocytic thrombocytopenia: a case series indicating 2 founder variants in the Mississippi Band of Choctaw Indians, Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin, Pathogenesis of myelofibrosis with myeloid metaplasia, Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals, Clinical utility gene card for: Glanzmann thrombasthenia, Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex, Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation, The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation, JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells, Novel function of FAXDC2 in megakaryopoiesis, The nuclear factor NF-kappaB pathway in inflammation, Platelets and megakaryocytes contain functional nuclear factor-kappaB, Inhibition of constitutive NF-κB activity induces platelet apoptosis via ER stress, NF-kappaB: a stress-regulated switch for cell survival, New regulators of NF-kappaB in inflammation, © 2021 by The American Society of Hematology, Copyright ©2023 by American Society of Hematology, https://doi.org/10.1182/bloodadvances.2020003172, Phagocytes, Granulocytes, and Myelopoiesis, Platelet count at study entry (range), ×10, White blood cell count at study entry (range), ×10. We also found that 42% of gene promotors have significant H3K27ac deposition, including ITGA2B, ITGB3, FOSL2, TAL1, JUND, and MAPK3 (supplemental Figure 5). Multivariate analysis was used to determine independent prognostic factors using a Cox proportional hazards regression model. For evaluation of B7H3 staining, we adopted a staining index by multiplying the score for the percentage of positive tumor cells by the intensity score, which obtained as the intensity staining (0, no staining; 1, weak; 2, moderate; 3, strong) and the percentage of positive cells (0, <10%; 1, 10–40%; 2, 41–80%; 3, >80%). Li, Z. L. et al. The p value was assessed using the log-rank test (two-sided). Right, percentage of proliferating CD4+ T, proliferating CD8+ T, IFNγ+CD4+ T and IFNγ+CD8+ T (n = 3 biological independent samples). Error bars represent mean ± SD. f Cell lysates from the indicated cell lines were treated with PNGase F, Endo H, and O-glycanase for 1 h at 37 °C in vitro. Article  (A) Venn diagram illustrating the overlap of genes with hypomethylated or hypermethylated promoters and hypermethylated or hypomethylated gene bodies. Definition. PubMed  Overall, 58% of the DEGs had consistently hypomethylated promoters, and almost none were hypermethylated (Figure 2D). To assess the clinical significance of B7H3 upregulation in breast cancer, we first analyzed the expression of B7H3 mRNA in 113 pairs of breast cancer tissues from the Cancer Genome Atlas (TCGA) database. A list of the genes covered and details of the analysis pipeline are provided in supplemental Table 1. ADS  Die Therapie wird vor und nach der Operation mit dem Checkpointinhibitor Pembrolizumab ergänzt. Moreover, direct comparisons between the 12 TN patients and 6 patients with known mutations yielded limited significant differences (supplemental Figure 1B). Cancer Res. LentiCRISPR V2 plasmid was used as a negative control. Currently, monoclonal antibodies specifically targeting B7H3, such as MGA271, 8H9, MGC018, pyrrolobenzodiazepine-conjugated CD276, and Lutetium-177 Labeled Omburtamab antibody, are mainly dependent on antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-drug conjugates (ADC) effect47,48,49,50,51,52. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Keenan, T. E. & Tolaney, S. M. Role of immunotherapy in triple-negative breast cancer. Four patients had the JAK2V617F mutation. Triple-negative breast cancers or in short TNBCs are regarded as aggressive types of breast cancer and are the product of impaired expression of progesterone and estrogen receptors as well as human growth factor receptor 2 ( Bianchini et al., 2016 ). We acknowledge that a potential weakness of our work is the absence of comparison with reactive thrombocytosis patients; this topic could be assessed in future studies. The tumor cells were infected with viral particles for 24 h in the presence of polybrene (8 μg/ml), and positive stable cell lines were subsequently selected by puromycin for 3 days. Perez-Riverol, Y. et al. In the study, we identified that fucosyltransferase FUT8 was involved in modulating the core fucosylation of B7H3 at N-glycans in TNBC cells. Fucosylation, especially core fucosylation, is one of the most widely occurring cancer-associated changes in N-glycans11. To address this, we applied 2-fluoro-L-fucose (2F-Fuc), a potent and general inhibitor of cellular core fucosylation, to treat TNBC cells and detected the core fucosylation of B7H3. Here, we identify aberrant B7H3 glycosylation and show that N-glycosylation of B7H3 at NXT motif sites is responsible for its protein stability and immunosuppression in TNBC tumors. Cell Rep. 20, 1017–1028 (2017). Île-de-France is the compact region immediately surrounding Paris. PLoS ONE 10, e0130126 (2015). Es wird hier ebenfalls eine dosisdichte Chemotherapie empfohlen. Indeed, the combined treatment not only led to increased IFNγ+CD4+ T, IFNγ+CD8+ T, and IFNγ+NK populations (Fig. 38, 4283–4291 (2020). Das triple-negative Mammakarzinom, kurz TNBC, ist eine Form des Brustkrebses, bei der weder der Östrogenrezeptor (ER), noch der Progesteronrezeptor (PR), noch der Wachstumsfaktorrezeptor HER2 maßgeblich auf der Zelloberfläche der Tumorzellen nachgewiesen werden kann. Similar results were also observed in HEK293T cells (Supplementary Fig. After mice were killed, the tumor tissues were excised and weighed. Red closed circle, glycosylated B7H3; blue star, non-glycosylated B7H3. It is important to note that the absence of mutations does not exclude alternative disease drivers, as it is well established that WES cannot detect fusion oncogenes, mutations in regulatory sequences, or alterations in gene expression.